

# Financial Tear Sheet

## Corporate Profile

Proteon Therapeutics is working to deliver a new future for patients and families affected by kidney and vascular diseases, where innovation drives health improvement and healthcare professionals have the tools they need to improve patient outcomes. Proteon is a late-stage biopharmaceutical company developing potentially transformative treatment options to address some of the most urgent needs in chronic kidney disease (CKD) and peripheral artery disease (PAD) with the goal of redefining how these diseases are treated. Proteon’s lead product candidate, vonapanitase, is a first-in-class recombinant human elastase designed to treat vessel injury that leads to blood vessel blockage and reduced blood flow. Proteon is evaluating vonapanitase in a Phase 3 trial in patients with CKD undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis and in a Phase 1 program in patients suffering from PAD.

## IR Contact

George Eldridge  
 781-890-0102 x1026  
 investor@proteontherapeutics.com

## Media Contact

Ann Stanesa  
 Ten Bridge Communications  
 617-230-0347  
 proteon@tenbridgecommunications.com

## Stock Information

PRTO (Common Stock)	
<b>Exchange</b>	NASDAQ GS (US Dollar)
<b>Price</b>	<b>\$1.85</b>
<b>Change (%)</b>	0.00 (0.00%)
<b>Volume</b>	54,560
<b>52 Week Low</b>	\$1.10
<b>Market Cap</b>	\$32,595,923
<b>Rolling EPS</b>	-2.22
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	17,619,418
Data as of 12/15/17 3:59 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

## Recent Press Releases & Upcoming Events

11/08/17

Proteon Therapeutics to Present at the Stifel 2017  
Healthcare Conference November 15th

There are currently no events scheduled.

11/07/17

Proteon Therapeutics Announces Third Quarter 2017  
Financial Results

09/05/17

Proteon Therapeutics to Present at the Baird 2017  
Global Healthcare Conference September 7, 2017

## SEC Filings

<b>Filing Date</b>	<b>Form</b>
12/15/17	4
12/04/17	4
12/04/17	SC 13D/A
11/16/17	4

## Corporate Governance

Timothy P. Noyes	President and Chief Executive Officer
Steven K. Burke, M.D.	Senior Vice President and Chief Medical Officer
George A. Eldridge	Senior Vice President and Chief Financial Officer
Daniel P. Gottlieb	Vice President, Corporate Development
Scott Toner	Senior Vice President, Marketing
Pamela Gustafson	Vice President, Clinical Research
Matthew Kowalsky	Vice President, Legal
John Najim	Vice President, Manufacturing and Process Development
Marco Wong, M.D., Ph.D.	Medical Director
John Najim	Vice President, Manufacturing and Process Development

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.